GlassScriptPhysician profile
Janet Pearl
NPI 1346237674
$5,327.03
in general payments reported to CMS, 2019-2025
28 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $221 · 2021: $360 · 2022: $388 · 2023: $490 · 2024: $1,231 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Travel and Lodging: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.46 |
| Travel and Lodging | $755.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,685.70 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $939.71 | 2022-2025 | |
| Stimwave Technologies Incorporated | $493.55 | 2019-2022 | |
| Pfizer INC. | $309.76 | 2020-2025 | |
| Painteq LLC | $239.34 | 2021-2024 | Painteq |
| Vertos Medical, INC. | $229.24 | 2021-2024 | Mild Device Kit |
| Allergan, INC. | $212.70 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $169.76 | 2024-2025 | Xeomin |
| Fidia Pharma USA INC. | $124.59 | 2019-2023 | Triluron, Hymovis |
| Abbott Laboratories | $110.97 | 2021-2024 | Proclaim |
| Biohaven Pharmaceuticals, INC. | $106.13 | 2020-2021 | |
| Globus Medical, INC. | $101.06 | 2025 | Senza |
| Amgen INC. | $100.77 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $79.36 | 2022 | |
| Medtronic, INC. | $59.64 | 2021-2023 | Intellis Adaptivestim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $44.23 | 2019-2021 | |
| Curonix LLC | $41.82 | 2022 | |
| Stryker Corporation | $38.63 | 2024 | Mild Device Kit |
| Bioventus LLC | $38.37 | 2019 | |
| Supernus Pharmaceuticals, INC. | $37.65 | 2019 | |
| Medtronic USA, INC. | $31.13 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.98 | 2023 | Dysport |
| Relievant Medsystems, INC. | $24.33 | 2023 | Intracept |
| Scilex Pharmaceuticals INC. | $19.40 | 2019 | |
| Nevro Corp. | $18.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.30 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $14.74 | 2025 | |
| Merz North America, INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Pearl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.